Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TNGX
stocks logo

TNGX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
625.50K
-84.81%
-0.337
-0.84%
0.00
-100%
-0.293
-18.52%
0.00
-100%
-0.300
-14.29%
Estimates Revision
The market is revising Upward the revenue expectations for Tango Therapeutics, Inc. (TNGX) for FY2025, with the revenue forecasts being adjusted by 1.04% over the past three months. During the same period, the stock price has changed by 42.65%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.04%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-18.77%
In Past 3 Month
Stock Price
Go Up
up Image
+42.65%
In Past 3 Month
Wall Street analysts forecast TNGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNGX is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast TNGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNGX is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.900
sliders
Low
11.00
Averages
13.00
High
15.00
Current: 9.900
sliders
Low
11.00
Averages
13.00
High
15.00
Stifel
NULL -> Buy
initiated
$15
2025-12-03
New
Reason
Stifel
Price Target
$15
2025-12-03
New
initiated
NULL -> Buy
Reason
Stifel initiated coverage of Tango Therapeutics with a Buy rating and $15 price target. The firm views the company's vopimetostat as a potential "best-in-class" PRMT5 inhibitor. The drug could become the standard of care in in second-line MTAP-deleted pancreatic ductal adenocarcinoma, the analyst tells investors in a research note. Stifel sees peak global revenue of $1.2B by 2035.
B. Riley
Buy
downgrade
$12 -> $11
2025-11-18
Reason
B. Riley
Price Target
$12 -> $11
2025-11-18
downgrade
Buy
Reason
B. Riley lowered the firm's price target on Perspective Therapeutics (CATX) to $11 from $12 and keeps a Buy rating on the shares. Ahead of the data update at ASCO 2026, the firm views Perspective Therapeutics as having a similar setup and similar competitive landscape to that Tango Therapeutics (TNGX) had five months ago, the analyst tells investors in a research note.
B. Riley
NULL -> Buy
maintain
$8 -> $14
2025-11-18
Reason
B. Riley
Price Target
$8 -> $14
2025-11-18
maintain
NULL -> Buy
Reason
B. Riley raised the firm's price target on Tango Therapeutics to $14 from $8 and keeps a Buy rating on the shares. Tango's enterprise valuation expansion from $200M to $800M suggests the market values vopimetostat's safety differentiation, the analyst tells investors in a research note.
Wolfe Research
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research initiated coverage of Tango Therapeutics with a Peer Perform rating and no price target. Vopimetostat's signal in pancreatic cancer "looks weak," the analyst tells investors.
Guggenheim
Michael Schmidt
Buy
maintain
$10 -> $12
2025-10-24
Reason
Guggenheim
Michael Schmidt
Price Target
$10 -> $12
2025-10-24
maintain
Buy
Reason
Guggenheim analyst Michael Schmidt raised the firm's price target on Tango Therapeutics to $12 from $10 and keeps a Buy rating on the shares after the company disclosed Phase 1/2 vopimetostat data in solid tumor patients. The firm is updating its model and estimates and increasing its odds of success assumption for vopimetostat following the data.
Piper Sandler
Overweight
initiated
$11
2025-08-19
Reason
Piper Sandler
Price Target
$11
2025-08-19
initiated
Overweight
Reason
As previously reported, Piper Sandler initiated coverage of Tango Therapeutics with an Overweight rating and $11 price target. The firm thinks investors are starting to regain confidence in the synthetic lethality space and see potential for Tango's TNG462 following the positive competitor readthrough presented at ASCO earlier this year. The firm thinks the size and length of follow-up on the second half clinical update in pancreatic cancer and NSCLC can provide support for the potentially differentiated durability of TNG462 and "begin de-risking potential blockbuster opportunities," the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Tango Therapeutics Inc (TNGX.O) is -7.76, compared to its 5-year average forward P/E of -5.95. For a more detailed relative valuation and DCF analysis to assess Tango Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.95
Current PE
-7.76
Overvalued PE
-2.83
Undervalued PE
-9.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.50
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.72
Undervalued EV/EBITDA
-5.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
98.99
Current PS
0.00
Overvalued PS
472.39
Undervalued PS
-274.41
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

TNGX News & Events

Events Timeline

(ET)
2025-11-04
09:02:14
Tango Therapeutics Announces Q3 Earnings Per Share of 14 Cents, Exceeding Consensus Estimate of 7 Cents
select
2025-10-23 (ET)
2025-10-23
07:22:54
Tango Therapeutics sets price for 21 million shares at $8.66 in underwritten offering
select
2025-10-23
07:05:45
Tango Therapeutics reveals encouraging results from Phase 1/2 trial of vopimetostat
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-26Globenewswire
Tango Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
  • Conference Participation: Dr. Adam Crystal, President of R&D at Tango Therapeutics, is scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3 at 1:30 PM ET, showcasing the company's latest advancements in precision medicine, which is expected to attract investor and industry attention.
  • Live Webcast: The event will be available via live webcast on the company's website under the 'Investors' tab, enhancing investor engagement, and a replay will be archived for 90 days post-event, ensuring that investors who cannot attend live can still access key information.
  • Company Background: Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and developing precision therapies for cancer treatment, leveraging the genetic principle of synthetic lethality to target critical cancer pathways, demonstrating its innovative potential in cancer therapy.
  • Investor Relations: By providing media contact information, the company emphasizes its commitment to investors and media, aiming to enhance market trust and corporate image through transparent communication.
[object Object]
Preview
7.0
11-13Reuters
Trump grants clemency to British billionaire Joe Lewis

  • Pardon Granted: U.S. President Donald Trump has pardoned British billionaire Joe Lewis, who pleaded guilty to insider trading in New York last year.

  • Background on Lewis: Lewis, who is in his late 80s and controls a majority of Tottenham Hotspur, was sentenced to pay a $5 million fine and serve three years of probation for passing inside information to friends and associates.

  • Previous Pardons: Lewis joins a list of wealthy individuals, including Binance founder Changpeng Zhao and Nikola founder Trevor Milton, who have received pardons from Trump during his second term.

  • Lewis' Statement: Following the pardon, Lewis expressed relief and stated he looks forward to enjoying retirement while his family continues to build their businesses.

[object Object]
Preview
4.0
10-27NASDAQ.COM
Tango Therapeutics (TNGX) Receives Upgrade to Buy: Reasons Explained

  • Zacks Rank Upgrade: Tango Therapeutics, Inc. (TNGX) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which are crucial for stock price movements.

  • Earnings Estimate Revisions: The Zacks Consensus Estimate for Tango has increased by 23.3% over the past three months, reflecting analysts' growing confidence in the company's future earnings potential.

  • Investment Strategy: The Zacks rating system, which balances buy and sell ratings, positions Tango in the top 20% of stocks based on earnings estimate revisions, suggesting it may outperform the market in the near term.

  • Market Implications: Rising earnings estimates and the Zacks upgrade imply an improvement in Tango's underlying business, likely leading to increased buying pressure and a potential rise in stock price.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Tango Therapeutics Inc (TNGX) stock price today?

The current price of TNGX is 9.9 USD — it has increased 3.45 % in the last trading day.

arrow icon

What is Tango Therapeutics Inc (TNGX)'s business?

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.

arrow icon

What is the price predicton of TNGX Stock?

Wall Street analysts forecast TNGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNGX is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Tango Therapeutics Inc (TNGX)'s revenue for the last quarter?

Tango Therapeutics Inc revenue for the last quarter amounts to 53.81M USD, increased 363.61 % YoY.

arrow icon

What is Tango Therapeutics Inc (TNGX)'s earnings per share (EPS) for the last quarter?

Tango Therapeutics Inc. EPS for the last quarter amounts to 0.13 USD, decreased -148.15 % YoY.

arrow icon

What changes have occurred in the market's expectations for Tango Therapeutics Inc (TNGX)'s fundamentals?

The market is revising Upward the revenue expectations for Tango Therapeutics, Inc. (TNGX) for FY2025, with the revenue forecasts being adjusted by 1.04% over the past three months. During the same period, the stock price has changed by 42.65%.
arrow icon

How many employees does Tango Therapeutics Inc (TNGX). have?

Tango Therapeutics Inc (TNGX) has 155 emplpoyees as of December 05 2025.

arrow icon

What is Tango Therapeutics Inc (TNGX) market cap?

Today TNGX has the market capitalization of 1.33B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free